News of Note—Indian vaccine controversy, Genocea and more
admin 2nd October 2018 Uncategorised 0Here is some other vaccine news of note for the week. More: News of Note—Indian vaccine controversy, Genocea and more Source: fierce
read more
Here is some other vaccine news of note for the week. More: News of Note—Indian vaccine controversy, Genocea and more Source: fierce
read moreJust hours after Pfizer unveiled its CEO succession plan, industry watchers were already buzzing away on one key question: Will incoming chief Albert Bourla go after M&A deals? A megadeal, even? More: Will new Pfizer CEO Bourla get back on
read moreBayer’s divisions are trading at a discount, and a breakup could not only rev that up but also focus the company and potentially free up cash for deals that would beef up its less-than-exciting pharma pipeline, a Bernstein analyst figures.
read moreAmerisourceBergen agreed on Monday to pay $625 million to resolve civil charges against the company that a former subsidiary repackaged millions of vials of cancer drugs to harvest and sell their overfills. More: AmerisourceBergen to pay 5M to settle whistleblower
read moreLast week, investors concerned about generics trends and migraine competition cratered Teva’s shares. But did they really need to worry? Analysts disagree. More: Was last week's Teva sell-off warranted? Depends who you ask Source: fierce
read moreThe government has unveiled the winning projects of the latest Digital Health Catalyst competition, which will each win a slice of £17 million handed out by the Industrial Strategy Challenge Fund to help fuel their progress. More: Digital health projects
read more© 1994 - 2026 B.M. Pharmaceuticals